Who is sponsoring NCT04332367?

NCT04332367 is sponsored by Abramson Cancer Center at Penn Medicine.

What condition does NCT04332367 study?

NCT04332367 studies Non-small Cell Lung Cancer.

What drugs are being tested in NCT04332367?

Interventions: Carboplatin, Paclitaxel, Ramucirumab.

What is the status of NCT04332367?

NCT04332367 is currently RECRUITING.

Last reviewed 2026-01-05 · How we verify

Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab

NCT04332367 Phase 2 RECRUITING

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.

Details

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	Phase 2
Status	RECRUITING
Enrolment	59
Start date	2020-08-01
Completion	2026-04

Conditions

Non-small Cell Lung Cancer

Interventions

Carboplatin
Paclitaxel
Ramucirumab

Primary outcomes

To estimate overall response rate — 3 years
Overall response rate (ORR) as determined by RECIST criteria. Response will be defined by a complete response (CR) or partial response (PRO), confirmed or unconfirmed.

Countries

United States